| 784 | 4 | 23 |
| 下载次数 | 被引频次 | 阅读次数 |
肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一，它的形成是一个复杂的过程，其具体形成机制尚不明确，由于大多数HCC患者被诊断出来时已是晚期，通常已丧失良好的手术时机。而靶向药物的出现给当前HCC患者带来了新的希望，同时还可作为术后治疗措施，在HCC中发挥着巨大的作用。索拉非尼是第一个被用于治疗HCC的靶向药物，它可抑制肝肿瘤组织血管生成和细胞增殖，可诱导肝肿瘤细胞凋亡，进而提高部分肝癌患者的生存率。但据目前研究显示，有50%～60%HCC经治患者对该药物出现了敏感性下降。主要是由于索拉非尼使用后会抑制体内相关信号通路，从而致使耐药的发生，故进一步探索索拉非尼耐药机制，使其逆转索拉非尼耐药对于改善肝癌治疗的预后具有极其重要的临床价值。近些年来，许多学者致力研究索拉非尼通过Hippo/YAP及PI3K/Akt/mTOR信号通路介导细胞自噬与耐药性的产生有着密切联系。并探讨其耐药分子机制，使该领域获得了巨大的发展。因此，本篇文章主要从Hippo/YAP及PI3K/Akt/mTOR信号通路展开，探讨其与细胞自噬之间的关系以及介导的耐药机制，为索拉非尼治疗肝癌产生耐药性提供可靠的科学理论依据。
Abstract：Hepatocellular carcinoma( HCC) is one of the most common malignant tumors in the world. Its formation is a complex process, and the specific mechanism of its formation hasn't been cleared yet. Due to the fact that most HCC patients are diagnosed in the late stage, and they often lose good surgical opportunities. The emergence of targeted drugs has brought new hope to current HCC patients and can also serve as one of the measures for postoperative treatment, playing a huge role in treating HCC. Sorafenib is the first targeted drug used to treat HCC. It can induce apoptosis of liver tumor cells and inhibit proliferation and angiogenesis of liver tumor cells, so it can improve the survival rate of some patients. However, according to current research, 50%-60% of HCC patients experience a decrease in sensitivity to the drug. It is mainly because Sorafenib will inhibit relevant signaling pathways in vivo after using, which leads to the occurrence of drug resistance, so further exploring the mechanism of Sorafenib resistance and reversing Sorafenib resistance have extremely important clinical value for improving the prognosis of liver cancer treatment. In recent years, many scholars have devoted themselves to studying the close relationship between Sorafenib mediated autophagy and drug resistance through Hippo/YAP and PI3K/Akt/mTOR signaling pathways. And exploring the molecular mechanisms of drug resistance has led to significant development in this field. Therefore, this article mainly discusses the relationship between Hippo/YAP and PI3K/Akt/mTOR signaling pathways and autophagy, as well as the mechanism of drug resistance mediated by them, so as to provide a reliable Scientific theory basis for drug resistance of Sorafenib in the treatment of liver cancer.
1 Hashemi M,Nadafzadeh N,Imani MH,et al.Targeting and regulation of autophagy in hepatocellular carcinoma:Revisiting the molecular interactions and mechanisms for new therapy approaches[J].Cell Commun Signal,2023,21(1):32.
2 Tang W,Chen Z,Zhang W,Cheng Y,et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma:Theoretical basis and therapeutic aspects[J].Signal Transduct Target Ther,2020,5(1):87.
3 Huang L,Xiao D,Wu T,et.al.Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways[J].Am J Transl Res,2021,13(7):7508-7523.
4 Cao W,Liu X,Zhang Y,Li A,et al.BEZ235 increases the sensitivity of hepatocellular carcinoma to sorafenib by inhibiting PI3K/AKT/mTOR and inducing autophagy[J].Biomed Res Int,2021,2021:5556306.
5 Zhou Y,Wang Y,Zhou W,et al.YAP promotes multidrug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTORpathway[J].Cancer Cell Int,2019,19:179.
6 Huang A,Yang XR,Chung WY,et al.Targeted therapy for hepatocellular carcinoma[J].Signal Transduct Target Ther,2020,5(1):146.
7 Huang L,Xiao D,Wu T,et al.Phenformin synergistically sensitizes liver cancer cells to sorafenib by downregulating CRAF/ERK and PI3K/AKT/mTOR pathways[J].Am J Transl Res,2021,13(7):7508-7523.
8 Tang W,Chen Z,Zhang W,et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma:Theoretical basis and therapeutic aspects[J].Signal Transduct Target Ther,2020,5(1):87.
9 Zhu YJ,Zheng B,Wang HY,et al.New knowledge of the mechanisms of sorafenib resistance in liver cancer[J].Acta Pharmacol Sin,2017,38(5):614-622.
10 Matthaios D,Tolia M,Mauri D,et al.YAP/Hippo pathway and cancer immunity:It takes two to tango[J].Biomedicines,2021,9(12):1949.
11 Nishina H.Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation,homeostasis,and tumorigenesis[J].Cancer Sci,2022,113(6):1900-1908.
12 Lee YA,Noon LA,Akat KM,et al.Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap[J].Nat Commun,2018,9(1):4962.
13 Totaro A,Zhuang Q,Panciera T,et al.Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZmechanotransduction[J].Proc Natl Acad Sci U S A,2019,116(36):17848-17857.
14 Wang L,Zhu Z,Han L,et al.A curcumin derivative,WZ35,suppresses hepatocellular cancer cell growth via downregulating YAP-mediated autophagy[J].Food Funct,2019,10(6):3748-3757.
15 Totaro A,Zhuang Q,Panciera T,et al.Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZmechanotransduction[J].Proc Natl Acad Sci U S A,2019,116(36):17848-17857.
16 Zeng J,Xie H,Zhang ZL,et al.Apigenin regulates the migration,invasion,and autophagy of hepatocellular carcinoma cells by downregulating YAP[J].Neoplasma,2022,69(2):292-302.
17 Wang CZ,Yan GX,Dong DS,et al.LncRNA-ATBpromotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma[J].World J Gastroenterol,2019,25(35):5310-5322.
18 Chen Y,Henson ES,Xiao W,et al.Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia[J].Autophagy,2016,12(6):1029-1046.
19 Zhou TY,Zhuang LH,Hu Y,et al.Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells[J].Sci Rep,2016,6:30483.
20 Galadari S,Rahman A,Pallichankandy S,et al.Reactive oxygen species and cancer paradox:To promote or to suppress?[J].Free Radic Biol Med,2017,104:144-164.
21 Venkataramani V,Küffer S,Cheung KCP,et al.CD31expression determines redox status and chemoresistance in human angiosarcomas[J].Clin Cancer Res,2018,24(2):460-473.
22 Tian LY,Smit DJ,Jücker M.The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J].Int J Mol Sci,2023,24(3):2652.
23 Kim MN,Lee SM,Kim JS,Hwang SG.Preclinical efficacy of a novel dual PI3K/mTOR inhibitor,CMG002,alone and in combination with sorafenib in hepatocellular carcinoma[J].Cancer Chemother Pharmacol,2019,84(4):809-817.
24 Liu W,Zheng L,Zhang R,et al.Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma[J].Mol Cancer,2022,21(1):72.
25 Cui J,Shen HM,Lim LHK.The role of autophagy in liver cancer:Crosstalk in signaling pathways and potential therapeutic targets[J].Pharmaceuticals (Basel),2020,13(12):432.
26 Xu Z,Xu M,Liu P,et al.The mTORC2-Akt1 cascade is crucial for c-Myc to promote hepatocarcinogenesis in mice and humans[J].Hepatology,2019,70(5):1600-1613.
27 Xue S,Zhou Y,Zhang J,et al.Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma[J].Am J Transl Res,2019,11(4):2580-2589.
28 Wu Y,Zhang Y,Qin X,et al.PI3K/AKT/mTORpathway-related long non-coding RNAs:Roles and mechanisms in hepatocellular carcinoma[J].Pharmacol Res,2020,160:105195.
29 Maacha S,Bhat AA,Jimenez L,et al.Extracellular vesicles-mediated intercellular communication:Roles in the tumor microenvironment and anti-cancer drug resistance[J].Mol Cancer,2019,18(1):55.
30 Cao W,Liu X,Zhang Y,et al.BEZ235 increases the sensitivity of hepatocellular carcinoma to sorafenib by inhibiting PI3K/AKT/mTOR and inducing autophagy[J].Biomed Res Int,2021,2021:5556306.
31王媛，白玉贤.PI3K/AKT/mTOR信号通路介导索拉非尼治疗原发性肝癌耐药机制的研究进展[J].现代肿瘤医学，2019,27(21):3923-3926.
32 Shimizu S,Takehara T,Hikita H,et al.Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma[J].Int J Cancer,2012,131(3):548-557.
33 Dai N,Ye R,He Q,et al.Capsaicin and sorafenib combination treatment exerts synergistic anti-hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling[J].Oncol Rep,2018,40(6):3235-3248.
基本信息:
DOI：10.13210/j.cnki.jhmu.20230804.003
中图分类号:R735.7
引用信息:
[1]曹智,周塏,陈骋,等.索拉非尼基于Hippo/YAP及PI3K/Akt/mTOR信号通路介导细胞自噬在肝细胞癌中产生耐药机制研究进展[J].海南医学院学报,2024,30(06):475-480.DOI:10.13210/j.cnki.jhmu.20230804.003.
基金信息:
海南省自然科学基金资助项目（821QN391,ZDYF2022SHFZ283）~~
2023-08-07
2023-08-07
2023-08-07